gefitinib flomi 250 mg
genepharm s.a. - grecia - gefitinibum - compr. film. - 250mg - inhibitori de protein-kinaza inhibitori ai tirozin kinazei (egfr)
gefitinib polisano 250 mg
genepharm s.a. - grecia - gefitinibum - compr. film. - 250mg - alte antineoplazice inhibitori de protein-kinaza
phrompo 250 mg
alkaloid-int d.o.o. - slovenia - gefitinibum - compr. film. - 250mg - inhibitori de protein-kinaza inhibitori ai tirozin kinazei (egfr)
klp 9511+caro 2,0 premix pentru găini ouătoare 2%
compania koudijs animal nutrition b.v., olanda - complex - pulbere - găini ouătoare
blincyto
amgen europe b.v. - blinatumomab - leucemia limfoblastică limfoblastică a celulelor precursoare - agenți antineoplazici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
iressa
astrazeneca ab - gefitinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - iressa este indicat pentru tratamentul pacienților adulți cu avansat local sau metastatic non-cancer pulmonar cu celule mici cu activarea mutații ale epidermei-factor de crestere-receptor pentru tirozin-kinază.
gefitinib mylan
mylan pharmaceuticals limited - gefitinib - carcinom, pulmonar non-celulă mică - antineoplastic agents, protein kinase inhibitors - gefitinib mylan este indicat în monoterapie pentru tratamentul pacienților adulți cu avansat local sau metastatic non‑cancer pulmonar cu celule mici (nsclc), cu activarea mutații egfr‑tk.
gefitinib glenmark 250 mg
idifarma desarrollo farmaceutico, s.l. - spania - gefitinibum - compr. film. - 250mg - alte antineoplazice inhibitori de protein-kinaza
avastin 25 mg/ml concentrat pentru soluţie perfuzabilă
f.hoffmann-la roche ltd - bevacizumabum - concentrat pentru soluţie perfuzabilă - 25 mg/ml
avastin 25 mg/ml concentrat pentru soluţie perfuzabilă
f.hoffmann-la roche ltd - bevacizumabum - concentrat pentru soluţie perfuzabilă - 25 mg/ml